Rhumbline Advisers Has $14.56 Million Stock Holdings in TG Therapeutics, Inc. $TGTX

Rhumbline Advisers boosted its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 6.0% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 404,660 shares of the biopharmaceutical company’s stock after purchasing an additional 22,806 shares during the quarter. Rhumbline Advisers owned 0.25% of TG Therapeutics worth $14,564,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. Franklin Resources Inc. boosted its position in shares of TG Therapeutics by 25.3% during the second quarter. Franklin Resources Inc. now owns 91,387 shares of the biopharmaceutical company’s stock worth $3,289,000 after purchasing an additional 18,452 shares in the last quarter. DNB Asset Management AS raised its stake in TG Therapeutics by 47.8% during the 2nd quarter. DNB Asset Management AS now owns 10,527 shares of the biopharmaceutical company’s stock worth $379,000 after buying an additional 3,406 shares during the period. Inspire Advisors LLC bought a new position in TG Therapeutics during the second quarter worth about $202,000. Persistent Asset Partners Ltd lifted its holdings in TG Therapeutics by 137.2% during the second quarter. Persistent Asset Partners Ltd now owns 85,580 shares of the biopharmaceutical company’s stock worth $3,080,000 after acquiring an additional 49,508 shares in the last quarter. Finally, Rockefeller Capital Management L.P. acquired a new position in TG Therapeutics in the second quarter valued at about $420,000. Institutional investors own 58.58% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on TGTX. HC Wainwright assumed coverage on TG Therapeutics in a report on Monday, October 6th. They set a “buy” rating and a $60.00 price objective on the stock. B. Riley raised shares of TG Therapeutics to a “strong-buy” rating in a research note on Tuesday, November 4th. Wall Street Zen upgraded shares of TG Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. JPMorgan Chase & Co. increased their price objective on shares of TG Therapeutics from $46.00 to $49.00 and gave the stock an “overweight” rating in a research report on Monday, November 3rd. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of TG Therapeutics in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $50.25.

TG Therapeutics Price Performance

Shares of TGTX opened at $33.19 on Friday. The company has a 50 day moving average of $33.87 and a 200-day moving average of $33.91. The company has a quick ratio of 2.96, a current ratio of 3.86 and a debt-to-equity ratio of 0.89. The stock has a market capitalization of $5.27 billion, a P/E ratio of 89.69 and a beta of 1.95. TG Therapeutics, Inc. has a twelve month low of $25.28 and a twelve month high of $46.48.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Monday, November 3rd. The biopharmaceutical company reported $2.43 EPS for the quarter, topping the consensus estimate of $0.24 by $2.19. TG Therapeutics had a net margin of 13.31% and a return on equity of 26.05%. The business had revenue of $161.71 million during the quarter, compared to analysts’ expectations of $152.12 million. During the same quarter in the prior year, the company posted $0.02 earnings per share. The firm’s revenue was up 92.7% on a year-over-year basis. TG Therapeutics has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

Insider Activity

In related news, Director Sagar Lonial sold 20,852 shares of the stock in a transaction that occurred on Thursday, September 11th. The stock was sold at an average price of $32.24, for a total transaction of $672,268.48. Following the completion of the transaction, the director directly owned 94,061 shares of the company’s stock, valued at approximately $3,032,526.64. This represents a 18.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Yann Echelard sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $32.57, for a total value of $162,850.00. Following the completion of the transaction, the director owned 223,816 shares of the company’s stock, valued at approximately $7,289,687.12. This represents a 2.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 10.64% of the stock is owned by company insiders.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.